These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35401193)

  • 1. Case Report: Therapeutic Drug Monitoring of Polymyxin B During Continuous Renal Replacement Therapy in Two Pediatric Patients: Do Not Underestimate Extracorporeal Clearance.
    Xu C; Liu X; Cui Y; Huang X; Wang Y; Fan Y; Wu H; Li X; Guo B; Zhang J; Zhang Y
    Front Pharmacol; 2022; 13():822981. PubMed ID: 35401193
    [No Abstract]   [Full Text] [Related]  

  • 2. Population pharmacokinetics of polymyxin B and dosage strategy in critically ill patients with/without continuous renal replacement therapy.
    Luo X; Zhang Y; Liang P; Zhu H; Li M; Ding X; Zhang J
    Eur J Pharm Sci; 2022 Aug; 175():106214. PubMed ID: 35609779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing ceftaroline dosing in critically ill patients undergoing continuous renal replacement therapy.
    Kalaria S; Williford S; Guo D; Shu Y; Medlin C; Li M; Yeung SYA; Ali F; Jean W; Gopalakrishnan M; Heavner M
    Pharmacotherapy; 2021 Feb; 41(2):205-211. PubMed ID: 33438291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Finding the Dose for Ceftolozane-Tazobactam in Critically Ill Children with and without Acute Kidney Injury.
    Butragueño-Laiseca L; Troconiz IF; Grau S; Campillo N; García X; Padilla B; Fernández SN; Santiago MJ
    Antibiotics (Basel); 2020 Dec; 9(12):. PubMed ID: 33321721
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of continuous renal replacement therapy on the clinical efficacy and pharmacokinetics of polymyxin B in the treatment of severe pulmonary infection.
    Wang X; Zhou M; Wang X; Liu L; Zhang C
    Heliyon; 2024 Mar; 10(6):e27558. PubMed ID: 38509986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of polymyxin B in critically ill patients receiving continuous venovenous haemofiltration.
    Wang P; Xing H; Zhang F; Liu S; Lu Y; Zhang X; Yang J; Sun T
    Int J Antimicrob Agents; 2022 Jul; 60(1):106599. PubMed ID: 35526750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring of continuous-infusion acylovir for disseminated herpes simplex virus infection in a neonate receiving concurrent extracorporeal life support and continuous renal replacement therapy.
    Cies JJ; Moore WS; Miller K; Small C; Carella D; Conley S; Parker J; Shea P; Chopra A
    Pharmacotherapy; 2015 Feb; 35(2):229-33. PubMed ID: 25556960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant
    Yu Z; Liu X; Du X; Chen H; Zhao F; Zhou Z; Wang Y; Zheng Y; Bergen PJ; Li X; Sun R; Fang L; Li W; Fan Y; Wu H; Guo B; Li J; Yu Y; Zhang J
    Front Pharmacol; 2022; 13():975066. PubMed ID: 36588676
    [No Abstract]   [Full Text] [Related]  

  • 9. Population pharmacokinetics and limited sampling strategies of polymyxin B in critically ill patients.
    Pi MY; Cai CJ; Zuo LY; Zheng JT; Zhang ML; Lin XB; Chen X; Zhong GP; Xia YZ
    J Antimicrob Chemother; 2023 Mar; 78(3):792-801. PubMed ID: 36702748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
    Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
    Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing Antimicrobial Dosing for Critically Ill Patients with MRSA Infections: A New Paradigm for Improving Efficacy during Continuous Renal Replacement Therapy.
    Chen J; Li S; Wang Q; Wang C; Qiu Y; Yang L; Han R; Du Q; Chen L; Dong Y; Wang T
    Pharmaceutics; 2022 Apr; 14(4):. PubMed ID: 35456676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma concentrations of Colistin sulfate in a patient with septic shock on extracorporeal membrane oxygenation and continuous renal replacement therapy: a case report.
    Peng D; Zhang F; Lv P; Chen Y; Yang J; Zhu W; Zhu S; Shao H
    Ann Transl Med; 2022 May; 10(10):614. PubMed ID: 35722356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of meropenem in children with sepsis undergoing extracorporeal life support: A prospective observational study.
    Wang Y; Li Z; Chen W; Yan G; Wang G; Lu G; Chen C
    J Clin Pharm Ther; 2021 Jun; 46(3):754-761. PubMed ID: 33476064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.
    Isla A; Rodríguez-Gascón A; Trocóniz IF; Bueno L; Solinís MA; Maynar J; Sánchez-Izquierdo JA; Pedraz JL
    Clin Pharmacokinet; 2008; 47(3):173-80. PubMed ID: 18307371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of continuous renal replacement therapy on the plasma concentration of imipenem in severe infection patients with acute renal injury].
    Yu B; Liu L; Xing D; Zhao C; Hu Z
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2015 May; 27(5):359-65. PubMed ID: 26003640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of polymyxin B regimens for the treatment of carbapenem-resistant organism nosocomial pneumonia: a real-world prospective study.
    Tang T; Li Y; Xu P; Zhong Y; Yang M; Ma W; Xiang D; Zhang B; Zhou Y
    Crit Care; 2023 Apr; 27(1):164. PubMed ID: 37106370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy.
    Ulldemolins M; Vaquer S; Llauradó-Serra M; Pontes C; Calvo G; Soy D; Martín-Loeches I
    Crit Care; 2014 Jun; 18(3):227. PubMed ID: 25042938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patients.
    Hanafin PO; Kwa A; Zavascki AP; Sandri AM; Scheetz MH; Kubin CJ; Shah J; Cherng BPZ; Yin MT; Wang J; Wang L; Calfee DP; Bolon M; Pogue JM; Purcell AW; Nation RL; Li J; Kaye KS; Rao GG
    Clin Microbiol Infect; 2023 Sep; 29(9):1174-1181. PubMed ID: 37217076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness, nephrotoxicity, and therapeutic drug monitoring of polymyxin B in nosocomial pneumonia among critically ill patients.
    Ye Q; Wang Q; Chen Z; Chen W; Zhan Q; Wang C
    Clin Respir J; 2022 May; 16(5):402-412. PubMed ID: 35586931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An area under the concentration-time curve threshold as a predictor of efficacy and nephrotoxicity for individualizing polymyxin B dosing in patients with carbapenem-resistant gram-negative bacteria.
    Yang J; Liu S; Lu J; Sun T; Wang P; Zhang X
    Crit Care; 2022 Oct; 26(1):320. PubMed ID: 36258197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.